Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? Clin Adv Hematol Oncol. 2018 May;16(5):353-355 Authors: Postow MA PMID: 29851931 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research